Related Experiment Videos
Slow-acting, disease-modifying osteoarthritis agents
P S McNamara1, S A Johnston, R J Todhunter
1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
Abstract:
There is evidence to suggest that tetracyclines have benefit beyond their antimicrobial activity. The ability to inhibit metalloproteinase activity may provide a disease-modifying effect in OA, and available data suggest that further investigation is warranted. Controlled, double-blind, prospective clinical studies have not been completed. The canine cruciate ligament transection model studies are frequently cited as the most convincing in vivo evidence of a benefit of oral tetracycline therapy for the treatment of OA. Until more evidence becomes available, the use of tetracyclines as therapeutic agents for OA should be considered investigational.
Insights
Tetracyclines may offer benefits for osteoarthritis (OA) beyond their antibiotic properties by inhibiting metalloproteinases. Further clinical studies are needed to confirm their disease-modifying potential in OA treatment.
Area of Science:
- Pharmacology
- Rheumatology
- Veterinary Medicine
Background:
- Tetracyclines possess non-antimicrobial properties.
- Metalloproteinase inhibition is a potential mechanism for disease modification in osteoarthritis (OA).
Purpose of the Study:
- To evaluate the potential disease-modifying effects of tetracyclines in osteoarthritis.
- To assess the current evidence supporting tetracycline use for OA treatment.
Main Methods:
- Review of existing literature on tetracyclines and osteoarthritis.
- Analysis of in vivo studies, particularly canine models of OA.
Main Results:
- Evidence suggests tetracyclines inhibit metalloproteinases, indicating a potential therapeutic benefit in OA.
- Canine cruciate ligament transection models provide the most compelling in vivo data for oral tetracycline efficacy in OA.
Conclusions:
- Tetracyclines show promise as a disease-modifying agent for OA due to metalloproteinase inhibition.
- Current evidence, while suggestive, is insufficient; controlled clinical trials are required.
- The use of tetracyclines for OA remains investigational pending further research.